Skip to content

Trial Summary

This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and anti-tumor activity of IDE397 as a single agent and in combination with docetaxel, paclitaxel, gemcitabine/nab-paclitaxel and pemetrexed in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy or for whom no curative therapy is available. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).



ACTRN/NCT /ethics:


Scientific title:

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Sponsor / Cooperative group:

IDEAYA Biosciences

Trial & Patient Characteristics

Cancer TypeSolid Tumor
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer Stage-
Anticipated Start Date2023-04-14
Anticipated End Date2024-06-30

Participating Hospitals

HospitalSouthern Oncology Clinical Research Unit
Clinical Trial CoordinatorMeggan O'Riley
Phone0491 679 039
Principal InvestigatorGanessan Kichenadasse
Recruitment StatusRecruiting